Peilong Cao

494 citations
17 papers · 356 indexed · h-index 9
Topics
RNA modifications and cancer (4 papers)MicroRNA in disease regulation (3 papers)Cancer-related molecular mechanisms research (3 papers)

In The Last Decade

Peilong Cao

17 papers receiving 353 citations

Peers

Peilong Cao
Comparison fields: 5 of 80
  • Molecular Biology 180
  • Cancer Research 114
  • Oncology 60
  • Surgery 55
  • Pulmonary and Respiratory Medicine 40
Replace Xin Xiao with:
Xin Xiao China
Eduardo Sandes Argentina
Xiangshan Ren China
Zafar Iqbal Pakistan
Man Shang China
Christian Orlowski Australia
Yun‐Sil Lee South Korea
Shibo Yu China
Fei Xie China
Peilong Cao relative to Xin Xiao China Xin Xiao's profile →
Citations per field
00.5×9.3×
Xin Xiao · 1×
Citations per year

Countries citing papers authored by Peilong Cao

Since Specialization
Citations

This map shows the geographic impact of Peilong Cao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peilong Cao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peilong Cao more than expected).

Fields of papers citing papers by Peilong Cao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peilong Cao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peilong Cao. The network helps show where Peilong Cao may publish in the future.

Co-authorship network of co-authors of Peilong Cao

This figure shows the co-authorship network connecting the top 25 collaborators of Peilong Cao. A scholar is included among the top collaborators of Peilong Cao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peilong Cao. Peilong Cao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
#WorkIndexed citations
1 5
2
Prognostic nomogram for primary splenic lymphoma: a SEER database-based study.
2
3 9
4 109
5 21
6 20
7 46
8 4
9 7
10 5
11
[Relationship between histopathologic characteristics and epidermal growth factor receptor mutation in lung adenocarcinoma].
3
12 7
13 34
14 38
15 5
16 33
17 8

About Peilong Cao

Peilong Cao is a scholar working on Biophysics, Cancer Research and Oncology, having authored 17 papers that have together received 356 indexed citations. Recurring topics across this work include RNA modifications and cancer (4 papers), MicroRNA in disease regulation (3 papers) and Cancer-related molecular mechanisms research (3 papers). The work is most often cited by research in Cancer Research (114 citations), Biophysics (37 citations) and Urology (32 citations). Peilong Cao has collaborated with scholars based in China, United Kingdom and United States. Frequent co-authors include Wei Tian, Fei Qu, Lingling Yang, Yanqin Zhang, An Wang, Jinhai Fan, Dalin He, Rong Yan, Qi Guo and Dongmei Diao. Their work appears in journals such as Biochemical and Biophysical Research Communications, Experimental Cell Research and RSC Advances.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026